According to a recent 2019 update of the European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis, TNF inhibitors should be applied in patients with insufficient response to an initial course of conventional synthetic (cs) DMARDs (including methotrexate, sulfasalazine, leflunomide) and the presence of poor prognostic factors [41]. The gene discussed is TNF; the disease is rheumatoid arthritis.